Indication
Lobular Carcinoma of the Breast
3 clinical trials
5 products
Clinical trial
Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid TumoursStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Product
CrizotinibProduct
FulvestrantClinical trial
Integrating Minimally Invasive Biomarkers of Estrogen Signaling to Detect Endocrine Therapy Resistance in Metastatic Invasive Lobular Breast CancerStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
18F-FES PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer: a Phase II Prospective Cohort Study Evaluating the Performance of FES PET/MRI in Axillary Staging Compared With Axillary SurgeryStatus: Not yet recruiting, Estimated PCD: 2027-05-15
Product
FESProduct
Translational analysis